Skip to content

Evolus EOLS Return on equity

Return on equity at other companies

AbbVie logo
AbbVieABBV
89%+32.7pp

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%
P/S1.6×-0.6×

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Calculated from Evolus’s reported figures.

Based on trailing twelve months.

The official record: Evolus’s 10-Q, filed May 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Evolus's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's return on equity?
Evolus (EOLS) reported return on equity of -472.6% in Q1 2024.
How has Evolus's return on equity changed year-over-year?
Evolus's return on equity decreased by 144.5% year-over-year, from -193.3% to -472.6%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.